ScinoPharm Taiwan, Ltd (1789) Fair Value & Analysis

Healthcare · TW · Market cap 15.7B TWD

Analysis

ScinoPharm Taiwan, Ltd (1789) currently trades at 20.20 TWD, while our model-based Fair Value estimate is 5.26 TWD — implying the stock looks roughly 74.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

ScinoPharm Taiwan, Ltd., a pharmaceutical company, provides active pharmaceutical ingredient (API) development and manufacturing and injectable solutions in Taiwan, rest of Asia, Europe, and the Americas. It offers small molecules, peptide drugs, and steroids; drug products for anticancer, thromboembolic disorders, and osteoporosis; and contract analytical testing, sterile injectables contract manufacturing, and small molecules and peptide contract development and manufacturing organization services. The company was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.